Revelation Biosciences Inc. (NASDAQ: REVB) completed a definitive agreement to immediately exercise outstanding warrants, allowing the company to issue up to 13,065,000 shares of common stock at an exercise price of $0.86 per share. The transaction is expected to generate approximately $11 million in gross proceeds, providing a critical cash infusion for the pre‑revenue biotech.
The warrant exercise is part of a broader strategy to shore up the company’s balance sheet. Revelation reported a $12.7 million cash balance as of the end of the September 2025 quarter, up from $5.2 million at June 30 2025. The company’s nine‑month operating cash burn is estimated at $6.3 million, a figure that underscores the urgency of the capital raise. By converting warrants into equity, Revelation avoids taking on additional debt and preserves capital for clinical development and day‑to‑day operations.
The financing also mitigates dilution risk from future capital needs. In exchange for the immediate exercise, the company issued new Class J warrants, giving warrant holders the option to purchase shares at a favorable price in the future. While this introduces potential dilution, it also provides a mechanism for future capital if the company’s valuation improves.
Revelation’s CEO, James Rolke, emphasized the importance of the transaction: “The team continues to strategically maximize our financial resources to advance the Gemini program. This capital raise strengthens our runway and supports the next phases of clinical development.” The company’s Gemini candidate targets acute kidney injury and chronic kidney disease, and recent FDA agreement on the AKI approval pathway is a significant tailwind that bolsters investor confidence.
The warrant exercise is a key milestone for a company that has faced Nasdaq listing compliance challenges. By increasing cash reserves and potentially improving share price support, the transaction helps ensure continued compliance with Nasdaq’s minimum bid price and equity requirements, thereby maintaining market visibility and access to future capital markets.
The proceeds will be allocated to clinical development milestones, GMP manufacturing ramp‑up, and general operating expenses. The infusion extends the company’s runway, allowing it to focus on the Phase 1b study and regulatory engagement without the immediate pressure of debt servicing.
Revelation’s financial strategy reflects a balance between preserving capital for high‑risk clinical work and maintaining liquidity to navigate the uncertain biotech landscape. The $11 million raise positions the company to pursue its therapeutic pipeline while avoiding the leverage and covenants that come with debt financing.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.